Larisa Pavlovna Mendeleeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Larisa Pavlovna Mendeleeva has a total of 679 co-authors. Here are the top co-authors by number of shared publications:
- Maya V. Soloveva
National Medical Research Center for Hematology, Ministry of Health of Russia
26 shared publications - Valerii G. Savchenko
National Medical Research Center for Hematology
23 shared publications - Irina Germanovna Rekhtina
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
20 shared publications - Maksim Valerievich Solovev
National Medical Research Center for Hematology
18 shared publications L S Liubimova
17 shared publications- Elena Parovichnikova
National Medical Research Center of Hematology
15 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10336
KRAS/NRAS Mutation-Associated Transcriptional Dysregulation and NRL, CREM and IL6 Expression in Relation to Clinical Outcomes in Multiple Myeloma
Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy with variable responses to induction therapy that are not fully explained by current risk stratification systems. Mutations in RAS family genes (KRAS and NRAS) are prevalent in MM, yet contemporary risk stratification systems do not include them despite their oncogenic potential. Our previous findings showed reduced response depth to bortezomib-containing triplet induction regimens in the presence of RAS mutations. The aim of this study is to identify RAS pathway–related molecular targets and evaluate their relationship with clinical outcomes. Forty-four patients with newly diagnosed MM received bortezomib-based induction therapy (velcade + cyclophosphamide + dexamethasone, VCD or velcade + doxorubicin + dexamethasone, PAD/VCD). Bone marrow CD138+ plasma cells were isolated for transcriptome analysis. KRAS and NRAS gene mutations were identified by Sanger sequencing, and RNA sequencing was performed on the Illumina HiSeq 3000 platform. Gene expression was analyzed using Salmon and DESeq2. The clinical endpoints were depth of response, event-free survival (EFS), and overall survival (OS). Of the 66 candidate RAS-pathway related genes examined, five—CREM, NRL, IL6, MMP14 and MEF2B—showed significantly higher expression in samples with KRAS and NRAS gene mutations (t-test, p < 0.05). Lower NRL gene expression was associated with achieving CR + VGPR (HR 10.99, 95% CI: 1.26–534.66, p = 0.01). Elevated IL6 gene expression correlated with poorer OS (HR 3.18; p = 0.05), while increased CREM gene expression was associated with shorter EFS (HR 2.62; p = 0.01). The identified association between gene expression and survival was validated using publicly available external datasets (CREM: HR 2.43, 95% CI: 1.15–5.17, p = 0.017; IL6: HR 1.8, 95% CI: 1.41–2.3, p = 0.0000014). Increased expression of NRL, CREM, and IL6 genes in bone marrow plasma cells before treatment in MM patients was associated with adverse clinical outcomes and may reflect the molecular mechanisms underlying the negative effects of KRAS and NRAS gene mutations.
- 18 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10336
Open AccessKRAS/NRAS Mutation-Associated Transcriptional Dysregulation and NRL, CREM and IL6 Expression in Relation to Clinical Outcomes in Multiple Myeloma
Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy with variable responses to induction therapy that are not fully explained by current risk stratification systems. Mutations in RAS family genes (KRAS and NRAS) are prevalent in MM, yet contemporary risk stratification systems do not include them despite their oncogenic potential. Our previous findings showed reduced response depth to bortezomib-containing triplet induction regimens in the presence of RAS mutations. The aim of this study is to identify RAS pathway–related molecular targets and evaluate their relationship with clinical outcomes. Forty-four patients with newly diagnosed MM received bortezomib-based induction therapy (velcade + cyclophosphamide + dexamethasone, VCD or velcade + doxorubicin + dexamethasone, PAD/VCD). Bone marrow CD138+ plasma cells were isolated for transcriptome analysis. KRAS and NRAS gene mutations were identified by Sanger sequencing, and RNA sequencing was performed on the Illumina HiSeq 3000 platform. Gene expression was analyzed using Salmon and DESeq2. The clinical endpoints were depth of response, event-free survival (EFS), and overall survival (OS). Of the 66 candidate RAS-pathway related genes examined, five—CREM, NRL, IL6, MMP14 and MEF2B—showed significantly higher expression in samples with KRAS and NRAS gene mutations (t-test, p < 0.05). Lower NRL gene expression was associated with achieving CR + VGPR (HR 10.99, 95% CI: 1.26–534.66, p = 0.01). Elevated IL6 gene expression correlated with poorer OS (HR 3.18; p = 0.05), while increased CREM gene expression was associated with shorter EFS (HR 2.62; p = 0.01). The identified association between gene expression and survival was validated using publicly available external datasets (CREM: HR 2.43, 95% CI: 1.15–5.17, p = 0.017; IL6: HR 1.8, 95% CI: 1.41–2.3, p = 0.0000014). Increased expression of NRL, CREM, and IL6 genes in bone marrow plasma cells before treatment in MM patients was associated with adverse clinical outcomes and may reflect the molecular mechanisms underlying the negative effects of KRAS and NRAS gene mutations.
- Open Access
- 1 October 2026
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 30 (3) , 109-123
PET/CT with 18F-Fluorodeoxyglucose Diagnosis of Multiple Myeloma
Background . Modern hybrid PET/CT technology with 2-[ 18 F]fluoro-2-deoxy-B-glucose ( 18 F-FDG) is widely used in multiple myeloma (MM) patients. However, a number of issues in the evaluation of PET/CT results require further analysis and systematization. Aim: To investigate the role of FDG PET/CT in the diagnostics of MM. Materials and Methods. The analysis included the results of 40 18 F-FDG PET/CT examinations performed in 40 patients with MM before therapy. To systematize the description of PET/CT findings, based on the analysis of fused images (including abnormalities on CT, PET or both) three types of lesions were identified: focal, diffuse, and diffuse-focal. The analysis included visual and semiquantitative assessment. Results. In analyzed group (n = 40) 18F-FDG PET/CT showed focal lesions in 72% (n = 29) of cases, diffuse lesions — in 13% (n = 5), and diffuse-focal lesions in 15% (n = 6). In 33% (13/40) cases PET/CT results were 18 F-FDG-negative – all focal lesions. In the subgroup with focal and diffuse-focal type (n = 40), bone marrow lesions, according to 18 F-FDG increased uptake without corresponding structural abnormalities on CT, were detected in 5% (2/40). In the subgroup with osteolytic foci and plasmacytomas structural lesions showed significant differences in 18 F-FDG uptake intensity – SUL max values ranged from 1.6 to 22.2. This was observed both in the subgroups with focal and diffuse-focal type as a whole, as well as in individual patients, including lesions of comparable size. Conclusion . The obtained results demonstrate significant polymorphism of changes detected by 18 F-FDG PET/CT in MM patients at the diagnostic stage. Analysis of three PET/CT types of images – PET, CT, and fused – allowed for the identification of the main types of lesions: focal, diffuse, and diffuse-focal. The use of the proposed classification will allow for the standardization of PET/CT result descriptions and increase the accuracy of their assessment during follow-up studies in the course of MM patient treatment.
- 1 October 2026
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 30 (3) , 109-123
Open AccessPET/CT with 18F-Fluorodeoxyglucose Diagnosis of Multiple Myeloma
Background . Modern hybrid PET/CT technology with 2-[ 18 F]fluoro-2-deoxy-B-glucose ( 18 F-FDG) is widely used in multiple myeloma (MM) patients. However, a number of issues in the evaluation of PET/CT results require further analysis and systematization. Aim: To investigate the role of FDG PET/CT in the diagnostics of MM. Materials and Methods. The analysis included the results of 40 18 F-FDG PET/CT examinations performed in 40 patients with MM before therapy. To systematize the description of PET/CT findings, based on the analysis of fused images (including abnormalities on CT, PET or both) three types of lesions were identified: focal, diffuse, and diffuse-focal. The analysis included visual and semiquantitative assessment. Results. In analyzed group (n = 40) 18F-FDG PET/CT showed focal lesions in 72% (n = 29) of cases, diffuse lesions — in 13% (n = 5), and diffuse-focal lesions in 15% (n = 6). In 33% (13/40) cases PET/CT results were 18 F-FDG-negative – all focal lesions. In the subgroup with focal and diffuse-focal type (n = 40), bone marrow lesions, according to 18 F-FDG increased uptake without corresponding structural abnormalities on CT, were detected in 5% (2/40). In the subgroup with osteolytic foci and plasmacytomas structural lesions showed significant differences in 18 F-FDG uptake intensity – SUL max values ranged from 1.6 to 22.2. This was observed both in the subgroups with focal and diffuse-focal type as a whole, as well as in individual patients, including lesions of comparable size. Conclusion . The obtained results demonstrate significant polymorphism of changes detected by 18 F-FDG PET/CT in MM patients at the diagnostic stage. Analysis of three PET/CT types of images – PET, CT, and fused – allowed for the identification of the main types of lesions: focal, diffuse, and diffuse-focal. The use of the proposed classification will allow for the standardization of PET/CT result descriptions and increase the accuracy of their assessment during follow-up studies in the course of MM patient treatment.
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 384-391
The Value of Bone Marrow Flow Cytometry for Diagnosis, Evaluation of Hematologic Response, and Monitoring of Non-Measurable Disease in AL Amyloidosis Patients
BACKGROUND. In 8–20 % of patients with systemic AL amyloidosis (AL-A), a non-measurable disease is diagnosed which is characterized by low serum concentration of paraprotein and free light chains (FLCs). The standard immunochemical methods are not sufficiently robust in such clinical situation to evaluate the response to therapy and subsequent monitoring of the disease. AIM. To compare clinical and laboratory characteristics of AL-A patients with measurable and non-measurable diseases as well as to estimate the diagnostic value of multicolor flow cytometry of bone marrow (BM) in non-measurable AL-A. MATERIALS & METHODS. This prospective study enrolled 108 patients with newly diagnosed systemic AL-А, 20 (18.5 %) of them with a non-measurable disease (the difference between involved and uninvolved FLCs < 50 mg/L, paraprotein level < 10 g/L). All patients underwent clinical and laboratory examination including immunochemical analysis and 10-color flow cytometry of BM. RESULTS. In patients with non-measurable AL-A, severe cardiac failures occurred significantly less frequently (stage III: 16.7 % vs. 33.4 %; p = 0.03), whereas the rates of kidney and other organ involvements did not considerably differ. The median plasma cell (PC) count in non-measurable and measurable AL-A was 3.4 % and 5.2 %, respectively (p = 0.36) with the proportion of aberrant PCs in the total PC count being significantly lower in non-measurable disease (median 70.0 % vs. 92.2 %; p = 0.01). No correlation between the involved FLC concentration and the number of aberrant PCs was observed in non-measurable AL-A, while in measurable disease this correlation appeared to be significant (p = 0.003). The study demonstrated that the changes in aberrant PC clone by flow cytometry better correlated with the clinical response than with the changes of immunochemical parameters. Thus, the 5-year overall survival of patients with non-measurable and measurable AL-A did not differ (68 % and 61 %, respectively; p = 0.77). However, the 4-year clinical-progression-free (without vital organ dysfunction) survival was significantly lower in non-measurable disease, i.e., 23 % vs. 47 % (p = 0.04), which demonstrates that the standard immunochemical criteria alone used for response evaluation cannot provide sufficient control of the disease. CONCLUSION. Multicolor flow cytometry of BM is an effective additional method of diagnosis and monitoring of non-measurable AL-A disease, which allows to determine the tumor clone and objectively assess the therapy efficacy in cases when immunochemical methods appear to be limited. It seems to be advisable to regard flow cytometry as part of standard examination for this category of patients aiming to improve the accuracy of diagnosis and the evaluation of hematologic response.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 384-391
Open AccessThe Value of Bone Marrow Flow Cytometry for Diagnosis, Evaluation of Hematologic Response, and Monitoring of Non-Measurable Disease in AL Amyloidosis Patients
BACKGROUND. In 8–20 % of patients with systemic AL amyloidosis (AL-A), a non-measurable disease is diagnosed which is characterized by low serum concentration of paraprotein and free light chains (FLCs). The standard immunochemical methods are not sufficiently robust in such clinical situation to evaluate the response to therapy and subsequent monitoring of the disease. AIM. To compare clinical and laboratory characteristics of AL-A patients with measurable and non-measurable diseases as well as to estimate the diagnostic value of multicolor flow cytometry of bone marrow (BM) in non-measurable AL-A. MATERIALS & METHODS. This prospective study enrolled 108 patients with newly diagnosed systemic AL-А, 20 (18.5 %) of them with a non-measurable disease (the difference between involved and uninvolved FLCs < 50 mg/L, paraprotein level < 10 g/L). All patients underwent clinical and laboratory examination including immunochemical analysis and 10-color flow cytometry of BM. RESULTS. In patients with non-measurable AL-A, severe cardiac failures occurred significantly less frequently (stage III: 16.7 % vs. 33.4 %; p = 0.03), whereas the rates of kidney and other organ involvements did not considerably differ. The median plasma cell (PC) count in non-measurable and measurable AL-A was 3.4 % and 5.2 %, respectively (p = 0.36) with the proportion of aberrant PCs in the total PC count being significantly lower in non-measurable disease (median 70.0 % vs. 92.2 %; p = 0.01). No correlation between the involved FLC concentration and the number of aberrant PCs was observed in non-measurable AL-A, while in measurable disease this correlation appeared to be significant (p = 0.003). The study demonstrated that the changes in aberrant PC clone by flow cytometry better correlated with the clinical response than with the changes of immunochemical parameters. Thus, the 5-year overall survival of patients with non-measurable and measurable AL-A did not differ (68 % and 61 %, respectively; p = 0.77). However, the 4-year clinical-progression-free (without vital organ dysfunction) survival was significantly lower in non-measurable disease, i.e., 23 % vs. 47 % (p = 0.04), which demonstrates that the standard immunochemical criteria alone used for response evaluation cannot provide sufficient control of the disease. CONCLUSION. Multicolor flow cytometry of BM is an effective additional method of diagnosis and monitoring of non-measurable AL-A disease, which allows to determine the tumor clone and objectively assess the therapy efficacy in cases when immunochemical methods appear to be limited. It seems to be advisable to regard flow cytometry as part of standard examination for this category of patients aiming to improve the accuracy of diagnosis and the evaluation of hematologic response.
- Open Access
- 30 September 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (3) , 74-86
Predictors of autologous hematopoietic stem cell transplantation efficacy in patients with multiple myeloma
Background. Multiple myeloma (MM) remains a chronic hematologic malignancy. However, treatment outcomes have improved significantly due to the introduction of new targeted agents and high-dose therapy with autologous hematopoietic stem cell transplantation (auto-HSCT) into clinical practice. Several researchers have demonstrated that the efficacy of high-dose chemotherapy with auto-HSCT is superior to the use of low-intensity antitumor therapy alone, even in the era of targeted agents. Despite this, disease relapses after auto-HSCT remains a major problem limiting the potential for a biological cure for MM. It is important to identify significant prognostic factors whose correction could help prevent adverse outcomes in MM treatment. Aim. To determine the efficacy of auto-HSCT and to study progression-free survival (PFS) rates of MM patients depending on various clinical and laboratory parameters. Materials and methods. The single-center study included 803 patients with MM aged from 19 to 69 years (median 54 years), who underwent high-dose chemotherapy followed by single or tandem auto-HSCT from June 2000 to January 2025. The diagnosis was established in accordance with the criteria adopted by the International Myeloma Working Group (IMWG) with successively revised parameters and updated in 2014. Before the collection of hematopoietic stem cells all patients received induction therapy, including chemotherapeutic agents only (VAD, EDAP) in 38 cases, bortezomib in 765 cases, lenalidomide in 217 patients, and daratumumab in 51 cases. Single high-dose chemotherapy (melphalan 140–200 mg / m2) followed by auto-HSCT was administered to 515 patients, and tandem chemotherapy was administered to 288 patients. The antitumor response was assessed (revised for the retrospective group) for all patients according to the IMWG-2016 criteria after induction therapy, before auto-HSCT, and on day 100 thereafter. The study results were statistically analyzed using MedCalc. Results. Immunoglobulin G secretion was detected in 53 % of MM patients at disease onset, plasmacytomas were detected in 39 % of cases, and Durie–Salmon stage IIIA was diagnosed in 71 % of patients. After auto-HSCT, the rate of achieving stringent complete remission was 29 %, complete remission – 26 %, very good partial remission – 31 %, partial remission – 8 %, stabilization of disease – 2 %, and progression / relapse was recorded in 4 % of patients. A total of 320 (40 %) patients with MM showed an improvement in the antitumor response on the day 100 after the first auto-HSCT compared with the results of induction treatment. After completion of the high-dose phase, including one or two auto-HSCT, maintenance therapy was prescribed in 58 % of cases and in 42 % of cases, patients were monitored until progression without post-transplant treatment. The median PFS of patients was 36 months, while the probability of 5-year PFS was 32 %, and 10-year PFS – 20 %. The median PFS in the group of patients with standard cytogenetic risk was significantly higher and amounted to 40 months (95 % confidence interval 32–43) versus 26 months (95 % confidence interval 14–37) in the high-risk group (p 0.05). Based on the results of survival parameters assessment depending on the antitumor response achieved after auto-HSCT the median PFS was 104 months in case of stringent complete remission, 29 months for complete remission, 30 months for very good partial remission, 19 months for partial remission, 5 months for disease stabilization, and 4 months for progression / relapse on the day 100 after auto-HSCT (p 0.001). Multivariate Cox regression analysis showed that the probability of disease relapse / progression after autologous stem cell transplantation was statistically significantly associated with three factors: stage III (International Staging System), failure to achieve a stringent complete remission after auto-HSCT, and the absence of maintenance therapy (p 0.05). Conclusion. A long-term follow-up period allows confirming the high significance of auto-HSCT in the treatment algorithm for MM patients, as the probability of maintaining remission achieved after transplantation for 10 years was 20 %.
- 30 September 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (3) , 74-86
Open AccessPredictors of autologous hematopoietic stem cell transplantation efficacy in patients with multiple myeloma
Background. Multiple myeloma (MM) remains a chronic hematologic malignancy. However, treatment outcomes have improved significantly due to the introduction of new targeted agents and high-dose therapy with autologous hematopoietic stem cell transplantation (auto-HSCT) into clinical practice. Several researchers have demonstrated that the efficacy of high-dose chemotherapy with auto-HSCT is superior to the use of low-intensity antitumor therapy alone, even in the era of targeted agents. Despite this, disease relapses after auto-HSCT remains a major problem limiting the potential for a biological cure for MM. It is important to identify significant prognostic factors whose correction could help prevent adverse outcomes in MM treatment. Aim. To determine the efficacy of auto-HSCT and to study progression-free survival (PFS) rates of MM patients depending on various clinical and laboratory parameters. Materials and methods. The single-center study included 803 patients with MM aged from 19 to 69 years (median 54 years), who underwent high-dose chemotherapy followed by single or tandem auto-HSCT from June 2000 to January 2025. The diagnosis was established in accordance with the criteria adopted by the International Myeloma Working Group (IMWG) with successively revised parameters and updated in 2014. Before the collection of hematopoietic stem cells all patients received induction therapy, including chemotherapeutic agents only (VAD, EDAP) in 38 cases, bortezomib in 765 cases, lenalidomide in 217 patients, and daratumumab in 51 cases. Single high-dose chemotherapy (melphalan 140–200 mg / m2) followed by auto-HSCT was administered to 515 patients, and tandem chemotherapy was administered to 288 patients. The antitumor response was assessed (revised for the retrospective group) for all patients according to the IMWG-2016 criteria after induction therapy, before auto-HSCT, and on day 100 thereafter. The study results were statistically analyzed using MedCalc. Results. Immunoglobulin G secretion was detected in 53 % of MM patients at disease onset, plasmacytomas were detected in 39 % of cases, and Durie–Salmon stage IIIA was diagnosed in 71 % of patients. After auto-HSCT, the rate of achieving stringent complete remission was 29 %, complete remission – 26 %, very good partial remission – 31 %, partial remission – 8 %, stabilization of disease – 2 %, and progression / relapse was recorded in 4 % of patients. A total of 320 (40 %) patients with MM showed an improvement in the antitumor response on the day 100 after the first auto-HSCT compared with the results of induction treatment. After completion of the high-dose phase, including one or two auto-HSCT, maintenance therapy was prescribed in 58 % of cases and in 42 % of cases, patients were monitored until progression without post-transplant treatment. The median PFS of patients was 36 months, while the probability of 5-year PFS was 32 %, and 10-year PFS – 20 %. The median PFS in the group of patients with standard cytogenetic risk was significantly higher and amounted to 40 months (95 % confidence interval 32–43) versus 26 months (95 % confidence interval 14–37) in the high-risk group (p 0.05). Based on the results of survival parameters assessment depending on the antitumor response achieved after auto-HSCT the median PFS was 104 months in case of stringent complete remission, 29 months for complete remission, 30 months for very good partial remission, 19 months for partial remission, 5 months for disease stabilization, and 4 months for progression / relapse on the day 100 after auto-HSCT (p 0.001). Multivariate Cox regression analysis showed that the probability of disease relapse / progression after autologous stem cell transplantation was statistically significantly associated with three factors: stage III (International Staging System), failure to achieve a stringent complete remission after auto-HSCT, and the absence of maintenance therapy (p 0.05). Conclusion. A long-term follow-up period allows confirming the high significance of auto-HSCT in the treatment algorithm for MM patients, as the probability of maintaining remission achieved after transplantation for 10 years was 20 %.
- Open Access
- 23 July 2026
- Published by MDPI AG in Preprints.org
KRAS/NRAS Mutation-Associated Transcriptional Dysregulation Identifies NRL, CREM and IL-6 as Candidate Prognostic Biomarkers in Multiple Myeloma
Background: Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy with variable responses to induction therapy that are not fully explained by current risk stratification systems. Mutations in RAS family genes are prevalent in MM, yet contemporary risk stratification systems do not include them despite their oncogenic potential. Our previous findings showed reduced tumor cell sensitivity to bortezomib-containing triplet induction regimens in the presence of RAS mutations. The aim of this study is to identify RAS pathway–related molecular targets and evaluate their relationship with clinical outcomes. Methods: Forty-four patients with newly diagnosed MM received bortezomib-based induction therapy (VCD or PAD/VCD). Bone marrow CD138+ plasma cells were isolated for transcriptome analysis. KRAS and NRAS gene mutations were identified by Sanger sequencing, and RNA sequencing was performed on the Illumina HiSeq 3000 platform. Gene expression was analyzed using Salmon and DESeq2. The clinical endpoints were depth of response, progression-free survival (PFS), and overall survival (OS). Results: Of 66 candidate RAS-pathway genes examined, five—CREM, NRL, IL-6, MMP14 and MEB2B—showed significantly higher expression in samples with KRAS and NRAS gene mutations (t-test, p < 0.05). Lower NRL gene expression was associated with achieving a deep response (CR/VGPR; p = 0.02). Elevated IL6 gene expression correlated with poorer OS (HR 3.18; p = 0.05), while increased CREM gene expression was associated with shorter PFS (HR 2.62; p = 0.01). Conclusions: Increased expression of NRL, CREM, and IL6 genes could serve as potential prognostic biomarkers in MM and may reflect the molecular mechanisms underlying the adverse effects of KRAS and NRAS gene mutations.
- 23 July 2026
- Published by MDPI AG in Preprints.org
Open AccessKRAS/NRAS Mutation-Associated Transcriptional Dysregulation Identifies NRL, CREM and IL-6 as Candidate Prognostic Biomarkers in Multiple Myeloma
Background: Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy with variable responses to induction therapy that are not fully explained by current risk stratification systems. Mutations in RAS family genes are prevalent in MM, yet contemporary risk stratification systems do not include them despite their oncogenic potential. Our previous findings showed reduced tumor cell sensitivity to bortezomib-containing triplet induction regimens in the presence of RAS mutations. The aim of this study is to identify RAS pathway–related molecular targets and evaluate their relationship with clinical outcomes. Methods: Forty-four patients with newly diagnosed MM received bortezomib-based induction therapy (VCD or PAD/VCD). Bone marrow CD138+ plasma cells were isolated for transcriptome analysis. KRAS and NRAS gene mutations were identified by Sanger sequencing, and RNA sequencing was performed on the Illumina HiSeq 3000 platform. Gene expression was analyzed using Salmon and DESeq2. The clinical endpoints were depth of response, progression-free survival (PFS), and overall survival (OS). Results: Of 66 candidate RAS-pathway genes examined, five—CREM, NRL, IL-6, MMP14 and MEB2B—showed significantly higher expression in samples with KRAS and NRAS gene mutations (t-test, p < 0.05). Lower NRL gene expression was associated with achieving a deep response (CR/VGPR; p = 0.02). Elevated IL6 gene expression correlated with poorer OS (HR 3.18; p = 0.05), while increased CREM gene expression was associated with shorter PFS (HR 2.62; p = 0.01). Conclusions: Increased expression of NRL, CREM, and IL6 genes could serve as potential prognostic biomarkers in MM and may reflect the molecular mechanisms underlying the adverse effects of KRAS and NRAS gene mutations.
- Open Access
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 142-160
Analysis of one-year survival and mortality structure of patients with MM according to data from a multicenter Russian prospective study
Introduction . Before the introduction of targeted agents, multiple myeloma (MM) was characterized by low overall survival (OS) rates. Survival during the first year of life is a clear indicator of the effectiveness of not only antitumor therapy but also accompanying therapy. Analysis of the cause of death in the MM patient population will allow for refined approaches to diagnosis, antitumor treatment, and accompanying therapy. Aim : to determine the one-year OS rates in patients with newly diagnosed MM, to study the cause of death, and to estimate the probability of death within the first year after diagnosis. Materials and Methods . This multicenter prospective study, conducted from January 2015 to October 2018, included 3,184 patients (1,339 men and 1,845 women) with newly diagnosed MM from 40 regions of Russia, aged 24–90 years. One-year OS, one-year mortality, and causes of death were analyzed. Results . During the follow-up period, 2,307 deaths were recorded, 261 patients were lost to follow-up, and 616 patients continue to receive antitumor therapy or remain untreated. The median OS of patients with MM was 44 months, with a 5-year OS probability of 40 % and a 10-year OS probability of 17 %. Among 2,307 patients with documented fatal outcomes, causes of death were available in 1,350 cases. In 55.7 % (n = 752) of cases, death was determined to be due to MM progression, in 19 % (n = 257) to infectious complications, in 8.2 % (n = 111) to acute cardiovascular failure, and in 4 % (n = 54) to acute kidney injury. Pulmonary embolism was documented in 3.6 % of patients (n = 49), and mesenteric vascular thrombosis was diagnosed in 0.3 % (n = 4) of cases. Acute cerebrovascular accident, both ischemic and hemorrhagic, was diagnosed in 3.7 % (n = 50) of cases resulting in death. A second malignancy was the primary cause of death in 1.6 % (n = 22) of patients with MM. The one-year OS rate for patients newly diagnosed with myeloma from 2015 to 2018 was 82 %. The 5-year probability of death from myeloma progression was 31 %, while the 1-year probability was 9 %. Meanwhile, the 5-year probability of death from causes unrelated to myeloma progression was 45 %, while the 1-year probability was 11 %. Conclusion . The probability of death from causes unrelated to refractory myeloma was comparable across all age cohorts. This highlights the need for knowledge regarding concomitant therapy and the correction of comorbid factors. Differences in the one-year OS of patients with myeloma were demonstrated depending on the registration center, due to differences in access to second- and subsequent-line anticancer drugs. It is important to note the need to develop a separate treatment strategy for the cohort of patients with myeloma diagnosed in old age.
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 142-160
Open AccessAnalysis of one-year survival and mortality structure of patients with MM according to data from a multicenter Russian prospective study
Introduction . Before the introduction of targeted agents, multiple myeloma (MM) was characterized by low overall survival (OS) rates. Survival during the first year of life is a clear indicator of the effectiveness of not only antitumor therapy but also accompanying therapy. Analysis of the cause of death in the MM patient population will allow for refined approaches to diagnosis, antitumor treatment, and accompanying therapy. Aim : to determine the one-year OS rates in patients with newly diagnosed MM, to study the cause of death, and to estimate the probability of death within the first year after diagnosis. Materials and Methods . This multicenter prospective study, conducted from January 2015 to October 2018, included 3,184 patients (1,339 men and 1,845 women) with newly diagnosed MM from 40 regions of Russia, aged 24–90 years. One-year OS, one-year mortality, and causes of death were analyzed. Results . During the follow-up period, 2,307 deaths were recorded, 261 patients were lost to follow-up, and 616 patients continue to receive antitumor therapy or remain untreated. The median OS of patients with MM was 44 months, with a 5-year OS probability of 40 % and a 10-year OS probability of 17 %. Among 2,307 patients with documented fatal outcomes, causes of death were available in 1,350 cases. In 55.7 % (n = 752) of cases, death was determined to be due to MM progression, in 19 % (n = 257) to infectious complications, in 8.2 % (n = 111) to acute cardiovascular failure, and in 4 % (n = 54) to acute kidney injury. Pulmonary embolism was documented in 3.6 % of patients (n = 49), and mesenteric vascular thrombosis was diagnosed in 0.3 % (n = 4) of cases. Acute cerebrovascular accident, both ischemic and hemorrhagic, was diagnosed in 3.7 % (n = 50) of cases resulting in death. A second malignancy was the primary cause of death in 1.6 % (n = 22) of patients with MM. The one-year OS rate for patients newly diagnosed with myeloma from 2015 to 2018 was 82 %. The 5-year probability of death from myeloma progression was 31 %, while the 1-year probability was 9 %. Meanwhile, the 5-year probability of death from causes unrelated to myeloma progression was 45 %, while the 1-year probability was 11 %. Conclusion . The probability of death from causes unrelated to refractory myeloma was comparable across all age cohorts. This highlights the need for knowledge regarding concomitant therapy and the correction of comorbid factors. Differences in the one-year OS of patients with myeloma were demonstrated depending on the registration center, due to differences in access to second- and subsequent-line anticancer drugs. It is important to note the need to develop a separate treatment strategy for the cohort of patients with myeloma diagnosed in old age.
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3) , 264-274
Incidence and Prognostic Value of Bone and Extramedullary Plasmacytomas in Patients with Newly Diagnosed Multiple Myeloma: Data from a Prospective Population-Based Study
BACKGROUND. The etiology of plasmacytomas in multiple myeloma (MM) remains unclear, whereas the pathogenetic mechanisms of extramedullary lesions are of particular importance because of extremely poor prognosis. The incidence of bone and extramedullary plasmacytomas complicating the course of MM as well as the efficacy of therapy for this disease are still underresearched. AIM. To assess the incidence of bone and extramedullary plasmacytomas in patients with newly diagnosed MM (ndMM) and analyze the overall survival (OS) rates depending on whether soft-tissue components were detected. MATERIALS & METHODS. This multi-center prospective study enrolled 3184 ndMM patients (1339 men and 1845 women) from 40 regions of Russia, aged 24–90 years and treated during the period from January 2015 to October 2018. The electronic patient records included demographic, clinical, laboratory, and instrumental documentation data accessible on MM diagnosis date. Bortezomib-based regimens were administered in the first-line therapy to 94 % of patients. RESULTS. Bone and extramedullary plasmacytomas were diagnosed in 763 (24 %) out of 3184 ndMM patients. At disease onset, the median hemoglobin concentration was significantly higher in patients with bone (105 g/L) and extramedullary (102 g/L) plasmacytomas than in patients without them (95 g/L; p < 0.05). The median percentage of plasma cells in the bone marrow was significantly lower in cases of bone plasmacytoma accounting for 25 % vs. 30 % in cases of extramedullary components, and it was 31 % in patients without plasmacytomas at MM onset (p < 0.05). Most commonly, plasmacytomas were detected in the thoracic spine (24.3 %; n = 132) and ribs (13.6 %; n = 74). The median OS of patients without plasmacytomas was 46 months (95% confidence interval [95% CI] 43–49 months) vs. 38 months (95% CI 42–46 months) in patients with them (p = 0.1245). The median OS was 17 months (95% CI 10–35 months) in patients with extramedullary plasmacytomas and 13 months (95% CI 1–69 months) if soft-tissue components were detected in the bones of the lower extremities. CONCLUSION. The course of ndMM is complicated by bone plasmacytomas in 23 % of cases and extramedullary plasmacytomas in 1 % of cases. The antitumor response rate as well as the OS rates are similar in patients with and without bone plasmacytomas. Extramedullary lesions in MM are associated with extremely low rate of OS with the median not exceeding 17 months.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3) , 264-274
Open AccessIncidence and Prognostic Value of Bone and Extramedullary Plasmacytomas in Patients with Newly Diagnosed Multiple Myeloma: Data from a Prospective Population-Based Study
BACKGROUND. The etiology of plasmacytomas in multiple myeloma (MM) remains unclear, whereas the pathogenetic mechanisms of extramedullary lesions are of particular importance because of extremely poor prognosis. The incidence of bone and extramedullary plasmacytomas complicating the course of MM as well as the efficacy of therapy for this disease are still underresearched. AIM. To assess the incidence of bone and extramedullary plasmacytomas in patients with newly diagnosed MM (ndMM) and analyze the overall survival (OS) rates depending on whether soft-tissue components were detected. MATERIALS & METHODS. This multi-center prospective study enrolled 3184 ndMM patients (1339 men and 1845 women) from 40 regions of Russia, aged 24–90 years and treated during the period from January 2015 to October 2018. The electronic patient records included demographic, clinical, laboratory, and instrumental documentation data accessible on MM diagnosis date. Bortezomib-based regimens were administered in the first-line therapy to 94 % of patients. RESULTS. Bone and extramedullary plasmacytomas were diagnosed in 763 (24 %) out of 3184 ndMM patients. At disease onset, the median hemoglobin concentration was significantly higher in patients with bone (105 g/L) and extramedullary (102 g/L) plasmacytomas than in patients without them (95 g/L; p < 0.05). The median percentage of plasma cells in the bone marrow was significantly lower in cases of bone plasmacytoma accounting for 25 % vs. 30 % in cases of extramedullary components, and it was 31 % in patients without plasmacytomas at MM onset (p < 0.05). Most commonly, plasmacytomas were detected in the thoracic spine (24.3 %; n = 132) and ribs (13.6 %; n = 74). The median OS of patients without plasmacytomas was 46 months (95% confidence interval [95% CI] 43–49 months) vs. 38 months (95% CI 42–46 months) in patients with them (p = 0.1245). The median OS was 17 months (95% CI 10–35 months) in patients with extramedullary plasmacytomas and 13 months (95% CI 1–69 months) if soft-tissue components were detected in the bones of the lower extremities. CONCLUSION. The course of ndMM is complicated by bone plasmacytomas in 23 % of cases and extramedullary plasmacytomas in 1 % of cases. The antitumor response rate as well as the OS rates are similar in patients with and without bone plasmacytomas. Extramedullary lesions in MM are associated with extremely low rate of OS with the median not exceeding 17 months.
- Open Access
- 8 April 2026
- Published by Publishing House ABV Press in MD-Onco
- Vol. 6 (1) , 62-80
Epidemiological and clinical features of multiple myeloma in Russia: results of a multicenter prospective study
Background. Epidemiological studies aggregating data on newly diagnosed multiple myeloma (MM) from real-world clinical practice allow to analyze various clinical and laboratory parameters characterizing general trends in MM diagnosis, treatment outcomes, and life expectancy. Aim. To determine overall survival rates in patients with newly diagnosed MM and to examine factors influencing survival in a population-based study. Materials and methods. A total of 3,184 patients with a newly diagnosed MM from 40 regions of Russia were enrolled in a multicenter prospective study from January 2, 2015, to October 4, 2018. Complete registration of newly diagnosed cases was conducted at each of the 44 participating centers. Information on clinical and laboratory parameters, antitumor therapy regimens administered to patients, including autologous transplantation, was analyzed. Results. The median age of MM patients in Russia was 63 years. It was shown that 39 % of the patients belonged to the older age group 66–90 years, and the percentage of patients under 55 years was 22 %. Only 9 % of patients underwent bone marrow cytogenetic testing. The proportion of patients with kidney damage was 26 %, while 5 % of patients were dialysis dependent. It was shown that 78 % of patients were diagnosed with stage 3 according to Durie–Salmon system, and in 52 % of cases, stage III according to International Staging System was diagnosed. Induction therapy included the use of bortezomib in 94 % of cases, the VCD regimen (bortezomib + dexamethasone + cyclophosphamide) was mainly used, lenalidomide was prescribed extremely rarely – in 1 % of cases. The proportion of patients under 65 years of age who received at least one autologous hematopoietic stem cell transplant was only 18 %. With autologous hematopoietic stem cell transplantation, the median overall survival was 107 months, and in the case of maintenance therapy with lenalidomide, it increased to 129 months. Five-year overall survival of the entire group of patients was 40 %. In a multivariate analysis, independent predictors of worse overall survival were Durie–Salmon stage III, substage B, profound anemia (hemoglobin ≤80 g/L), albumin ≤30 g/L, and hypercalcemia (≥3 mmol/L). Conclusion. This multicenter prospective study of the epidemiological and clinical parameters of newly diagnosed multiple myeloma is unique in Russia in terms of coverage and follow-up duration (over 10 years). Analysis of treatment data for newly diagnosed multiple myeloma identified key issues in diagnosis and treatment.
- 8 April 2026
- Published by Publishing House ABV Press in MD-Onco
- Vol. 6 (1) , 62-80
Open AccessEpidemiological and clinical features of multiple myeloma in Russia: results of a multicenter prospective study
Background. Epidemiological studies aggregating data on newly diagnosed multiple myeloma (MM) from real-world clinical practice allow to analyze various clinical and laboratory parameters characterizing general trends in MM diagnosis, treatment outcomes, and life expectancy. Aim. To determine overall survival rates in patients with newly diagnosed MM and to examine factors influencing survival in a population-based study. Materials and methods. A total of 3,184 patients with a newly diagnosed MM from 40 regions of Russia were enrolled in a multicenter prospective study from January 2, 2015, to October 4, 2018. Complete registration of newly diagnosed cases was conducted at each of the 44 participating centers. Information on clinical and laboratory parameters, antitumor therapy regimens administered to patients, including autologous transplantation, was analyzed. Results. The median age of MM patients in Russia was 63 years. It was shown that 39 % of the patients belonged to the older age group 66–90 years, and the percentage of patients under 55 years was 22 %. Only 9 % of patients underwent bone marrow cytogenetic testing. The proportion of patients with kidney damage was 26 %, while 5 % of patients were dialysis dependent. It was shown that 78 % of patients were diagnosed with stage 3 according to Durie–Salmon system, and in 52 % of cases, stage III according to International Staging System was diagnosed. Induction therapy included the use of bortezomib in 94 % of cases, the VCD regimen (bortezomib + dexamethasone + cyclophosphamide) was mainly used, lenalidomide was prescribed extremely rarely – in 1 % of cases. The proportion of patients under 65 years of age who received at least one autologous hematopoietic stem cell transplant was only 18 %. With autologous hematopoietic stem cell transplantation, the median overall survival was 107 months, and in the case of maintenance therapy with lenalidomide, it increased to 129 months. Five-year overall survival of the entire group of patients was 40 %. In a multivariate analysis, independent predictors of worse overall survival were Durie–Salmon stage III, substage B, profound anemia (hemoglobin ≤80 g/L), albumin ≤30 g/L, and hypercalcemia (≥3 mmol/L). Conclusion. This multicenter prospective study of the epidemiological and clinical parameters of newly diagnosed multiple myeloma is unique in Russia in terms of coverage and follow-up duration (over 10 years). Analysis of treatment data for newly diagnosed multiple myeloma identified key issues in diagnosis and treatment.
- Open Access
- 23 March 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (1)
Mechanism of action of isatuximab in multiple myeloma. Literature review and clinical observation
Background. Multiple myeloma (MM) is a malignant lymphoproliferative disorder characterized by tumor plasma cells infiltrating the bone marrow. The pharmaceutical industry for the treatment of MM is experiencing a boom, characterized by the emergence of new-generation targeted drugs. It is important to describe the differences in the binding pattern of monoclonal antibodies to the CD38 protein and to analyze the treatment outcomes of MM patients treated with isatuximab, depending on various biological characteristics of the disease. Aim. To analyze the literature data on the isatuximab mechanism of action on tumor plasma cells, the features of monoclonal antibodies use depending on various factors and present a clinical observation of the isatuximab therapy in ММ patient and concomitant chronic obstructive pulmonary disease (COPD). Materials and methods. For this review, PubMed databases, clinical trial registries, and meeting libraries were searched from inception to December 20, 2025, using the terms reflecting multiple myeloma, isatuximab, daratumumab. We analyzed publications devoted to studying the mechanism of action of CD38 monoclonal antibodies and examining the efficacy of isatuximab in the treatment of multiple myeloma, depending on various factors. Our experience with the IsaPd regimen in a patient with relapsed / refractory MM and concomitant COPD is presented. Results. Isatuximab is the only CD38 antibody capable of inducing direct tumor cell apoptosis. The 1q abnormality did not affect survival in ММ patients treated with isatuximab-containing regimens. Due to limited complement-dependent cytotoxicity, isatuximab may be a preferred option for patients with COPD or asthma. The article describes our experience of isatuximab therapy in MM patient with COPD. The patient was diagnosed with MM in 2015 at the age of 57. Induction therapy consisted of bortezomib- and lenalidomide-containing regimens; an antitumor response was not achieved. Hematopoietic stem cell mobilization was performed after the DHAP regimen (cisplatin, cytarabine, dexamethasone) in combination with granulocyte colony-stimulating factor. To overcome resistance, therapy including carfilzomib was administered, achieving a very good partial remission. Autologous hematopoietic stem cell transplantation (melphalan 200 mg / m2) was then performed, followed by local radiation therapy to the plasmacytoma area, resulting in complete remission. Subsequently, due to relapse, therapy including ixazomib and lenalidomide was prescribed. In 2021, due to MM progression, sixth-line anti-relapse therapy with the IsaPd regimen was initiated. Despite COPD with frequent exacerbations requiring bronchodilator therapy, the patient tolerated isatuximab satisfactorily, with no adverse reactions. Twelve courses of therapy were completed, achieving partial remission. Conclusion. Monoclonal antibodies to CD38 are being integrated into induction therapy protocols for MM patients. This article describes the isatuximab mechanism of action and presents experience using IsaPd as a sixth-line therapy in a patient with MM and COPD. Along with a favorable safety profile, we also observed high treatment efficacy.
- 23 March 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (1)
Open AccessMechanism of action of isatuximab in multiple myeloma. Literature review and clinical observation
Background. Multiple myeloma (MM) is a malignant lymphoproliferative disorder characterized by tumor plasma cells infiltrating the bone marrow. The pharmaceutical industry for the treatment of MM is experiencing a boom, characterized by the emergence of new-generation targeted drugs. It is important to describe the differences in the binding pattern of monoclonal antibodies to the CD38 protein and to analyze the treatment outcomes of MM patients treated with isatuximab, depending on various biological characteristics of the disease. Aim. To analyze the literature data on the isatuximab mechanism of action on tumor plasma cells, the features of monoclonal antibodies use depending on various factors and present a clinical observation of the isatuximab therapy in ММ patient and concomitant chronic obstructive pulmonary disease (COPD). Materials and methods. For this review, PubMed databases, clinical trial registries, and meeting libraries were searched from inception to December 20, 2025, using the terms reflecting multiple myeloma, isatuximab, daratumumab. We analyzed publications devoted to studying the mechanism of action of CD38 monoclonal antibodies and examining the efficacy of isatuximab in the treatment of multiple myeloma, depending on various factors. Our experience with the IsaPd regimen in a patient with relapsed / refractory MM and concomitant COPD is presented. Results. Isatuximab is the only CD38 antibody capable of inducing direct tumor cell apoptosis. The 1q abnormality did not affect survival in ММ patients treated with isatuximab-containing regimens. Due to limited complement-dependent cytotoxicity, isatuximab may be a preferred option for patients with COPD or asthma. The article describes our experience of isatuximab therapy in MM patient with COPD. The patient was diagnosed with MM in 2015 at the age of 57. Induction therapy consisted of bortezomib- and lenalidomide-containing regimens; an antitumor response was not achieved. Hematopoietic stem cell mobilization was performed after the DHAP regimen (cisplatin, cytarabine, dexamethasone) in combination with granulocyte colony-stimulating factor. To overcome resistance, therapy including carfilzomib was administered, achieving a very good partial remission. Autologous hematopoietic stem cell transplantation (melphalan 200 mg / m2) was then performed, followed by local radiation therapy to the plasmacytoma area, resulting in complete remission. Subsequently, due to relapse, therapy including ixazomib and lenalidomide was prescribed. In 2021, due to MM progression, sixth-line anti-relapse therapy with the IsaPd regimen was initiated. Despite COPD with frequent exacerbations requiring bronchodilator therapy, the patient tolerated isatuximab satisfactorily, with no adverse reactions. Twelve courses of therapy were completed, achieving partial remission. Conclusion. Monoclonal antibodies to CD38 are being integrated into induction therapy protocols for MM patients. This article describes the isatuximab mechanism of action and presents experience using IsaPd as a sixth-line therapy in a patient with MM and COPD. Along with a favorable safety profile, we also observed high treatment efficacy.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 81-91
KRAS, NRAS, BRAF genes mutations in tumor cells of various localizations and their impact on the treatment outcomes of patients with multiple myeloma
Background. Multiple myeloma (MM) is a genetically complex disease in which different aberrations can be determined in tumors of different localizations. The impact of mutations in the RAS-ERK pathway genes on the MM course, despite numerous publications, is unclear. Aim. To evaluate mutations in the KRAS, NRAS, BRAF genes in plasma free circulating tumor DNA and CD138+ bone marrow cells and to analyze therapy results of MM patients at different stages depending on MAP kinase genes mutational status. Materials and methods. A prospective single-center study from September 2021 to December 2024 included 100 patients (45 men and 55 women) with newly diagnosed MM aged 29 to 83 years (median 55 years), 41 patients without plasmacytomas and 59 with plasmacytomas. The diagnosis was established in accordance with International Myeloma Working Group – 2014 criteria. Induction therapy was performed according to bortezomib-containing programs; the antitumor response was assessed according to International Myeloma Working Group – 2016 criteria. Analysis of KRAS, NRAS, BRAF genes mutations on DNA samples of CD138+ bone marrow cells was performed in all patients, in free circulating tumor DNA – in 81 patients. Statistical analysis was performed using the MedCalc program, and the Fisher criterion was also used. Survival analysis was performed using the Kaplan–Meier method, with statistical significance assessed using the log-rank test. Results. The frequency of KRAS, NRAS, BRAF genes mutations in free circulating tumor DNA and / or bone marrow in the total group was 50 %. The detection frequency of MAP kinase genes mutations in patients with and without plasmacytomas was comparable. No differences in detection frequency of high-risk cytogenetic aberrations were found in groups of patients with RAS-ERK pathway genes mutations and without them. A tendency towards a lower frequency of achieving complete remission after induction therapy was noted in patients with mutated gene status compared to patients without MAP kinase genes mutations (17 % versus 41 %; p = 0.07). At control time points after auto-transplantation, the trend remained: patients with MAP kinase genes mutations achieved a deep antitumor response 2 times less often compared to patients without mutations (30 % versus 59.5 %; p = 0.051). The probability of two-year progression-free survival of patients with MAP kinase genes mutations was significantly lower (p 0.05) – 62 % versus 92 % for patients without KRAS, NRAS, BRAF genes mutations. Conclusion. Due to the complex genetic structure and spatial anatomical heterogeneity of MM, the study of various localization tumors is extremely relevant. When mutations in the MAP kinase genes are detected, the antitumor response at various therapy stages is worse, and the probability of progression-free survival is significantly lower than in patients without mutations in these genes.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 81-91
Open AccessKRAS, NRAS, BRAF genes mutations in tumor cells of various localizations and their impact on the treatment outcomes of patients with multiple myeloma
Background. Multiple myeloma (MM) is a genetically complex disease in which different aberrations can be determined in tumors of different localizations. The impact of mutations in the RAS-ERK pathway genes on the MM course, despite numerous publications, is unclear. Aim. To evaluate mutations in the KRAS, NRAS, BRAF genes in plasma free circulating tumor DNA and CD138+ bone marrow cells and to analyze therapy results of MM patients at different stages depending on MAP kinase genes mutational status. Materials and methods. A prospective single-center study from September 2021 to December 2024 included 100 patients (45 men and 55 women) with newly diagnosed MM aged 29 to 83 years (median 55 years), 41 patients without plasmacytomas and 59 with plasmacytomas. The diagnosis was established in accordance with International Myeloma Working Group – 2014 criteria. Induction therapy was performed according to bortezomib-containing programs; the antitumor response was assessed according to International Myeloma Working Group – 2016 criteria. Analysis of KRAS, NRAS, BRAF genes mutations on DNA samples of CD138+ bone marrow cells was performed in all patients, in free circulating tumor DNA – in 81 patients. Statistical analysis was performed using the MedCalc program, and the Fisher criterion was also used. Survival analysis was performed using the Kaplan–Meier method, with statistical significance assessed using the log-rank test. Results. The frequency of KRAS, NRAS, BRAF genes mutations in free circulating tumor DNA and / or bone marrow in the total group was 50 %. The detection frequency of MAP kinase genes mutations in patients with and without plasmacytomas was comparable. No differences in detection frequency of high-risk cytogenetic aberrations were found in groups of patients with RAS-ERK pathway genes mutations and without them. A tendency towards a lower frequency of achieving complete remission after induction therapy was noted in patients with mutated gene status compared to patients without MAP kinase genes mutations (17 % versus 41 %; p = 0.07). At control time points after auto-transplantation, the trend remained: patients with MAP kinase genes mutations achieved a deep antitumor response 2 times less often compared to patients without mutations (30 % versus 59.5 %; p = 0.051). The probability of two-year progression-free survival of patients with MAP kinase genes mutations was significantly lower (p 0.05) – 62 % versus 92 % for patients without KRAS, NRAS, BRAF genes mutations. Conclusion. Due to the complex genetic structure and spatial anatomical heterogeneity of MM, the study of various localization tumors is extremely relevant. When mutations in the MAP kinase genes are detected, the antitumor response at various therapy stages is worse, and the probability of progression-free survival is significantly lower than in patients without mutations in these genes.